Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$3.40
-0.66 (-16.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-3.8M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1397.3%
↓Gross Margin
26.8%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+115.5%
FCF CAGR
—
FCF margin
-105.5%
FCF / Net income
0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.1M · net income $-5.9M · FCF $-3.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.1M | $3.1M | $22.3M | $139457.00 | $312938.00 |
| Net Income | $-5.9M | $-5.9M | $-568059.00 | $-6.9M | $-7.2M |
| EBITDA | $-5.2M | $-5.2M | $478645.00 | $-6.8M | $-7.2M |
| EPS | -0.32 | -0.32 | -0.02 | -0.45 | -0.48 |
| Gross Margin | 26.8% | 26.8% | 20.7% | -515.1% | -33.1% |
| Operating Margin | -173.9% | -173.9% | 1.9% | -4884.2% | -2303.0% |
| Net Margin | -189.3% | -189.3% | -2.5% | -4948.6% | -2313.2% |
| Balance Sheet | |||||
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.3M | $-3.3M | $-3.8M | $-5.1M | $-7.4M |
| Returns | |||||
| ROE | -1397.3% | -1397.3% | -28.4% | -268.2% | -78.2% |
| Valuation | |||||
| EV/EBITDA | — | — | 217.48 | — | — |
| P/B | 148.46 | 148.46 | 53.34 | 28.31 | 8.97 |
| Growth & Yield | |||||
| Revenue Growth | -85.9% | -85.9% | 15880.3% | -55.4% | — |
| EPS Growth | -1500.0% | -1500.0% | 95.5% | 6.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+46.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.32
Residual
+46.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.